Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 23;17(1):317.
doi: 10.1186/s13104-024-06969-4.

Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician survey

Christopher R Henry  1 , Scott D Walter  2 , Peter Y Chang  3 , David J Warrow  4 , Parisa Emami Naeini  5 , Kevin J Blinder  6 , Teresa Brevetti  7 , Mohamed Yassine  7 , Mark S Dacey  8 , David S Chu  9 , Veena R Raiji  10 , Lana M Rifkin  11 , Milan Shah  12 , Michael A Singer  13
Affiliations

Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician survey

Christopher R Henry et al. BMC Res Notes. .

Abstract

Objective: To obtain physicians' "real-world" perspectives on early experiences with triamcinolone acetonide suprachoroidal injection (SCS-TA) for treatment of patients with uveitic macular edema (UME).

Results: Twelve retina/uveitis specialists in the United States were surveyed about SCS-TA injection procedure and patient outcomes. Survey participants administered ≥ 291 SCS-TA injections to 243 patients with UME with various disease characteristics (etiologies, chronicity, and anatomical subtypes). Commonly reported reasons for SCS-TA adoption included potential for lowering the risk of steroid-associated intraocular pressure elevations versus intravitreal injections or implants (100%), potential for longer duration of action versus intravitreal steroid injections or implants (92%), and desire to use a new delivery modality (83%). Nearly all participants (92%) found injection procedure relatively easy post-training, with most (75%) procedurally comfortable after completing 2-5 injections. 58% of participants indicated that their patients gained 2-3 lines of vision by first follow-up visit, and 92% reported having patients who experienced 100-150 μm or greater reduction in central subfield thickness. Overall, 92% of participants were satisfied with SCS-TA treatment outcomes. Findings from this survey of early adopters of SCS-TA indicate that the suprachoroidal injection technique was easy to learn and resulted in favorable patient outcomes consistent with clinical trial data.

Keywords: Macular edema; Retina; Suprachoroidal injection; Survey; Treatment; Uveitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CRH reports being a consultant for Allergan, Alimera, Bausch + Lomb, Clearside Biomedical, Inc., and EyePoint Pharmaceuticals. SDW reports being a speaker for Apellis, Bausch + Lomb, Genentech/Roche, Regeneron, and Spark Therapeutics. SDW reports being a consultant for Allergan, Astellis/Iveric Bio, Bausch + Lomb, Castle Biosciences, EyePoint Pharmaceuticals/Alimera, Genentech/Roche, Ideaya Biosciences, Lupin, Novartis, and Regeneron. PEN reports receiving research and consulting fees from EyePoint Pharmaceuticals and Genentech. PEN is supported by the Knights Templar Eye Foundation, Inc. Career Starter grant. MAS reports receiving consulting fees from Aerie, Alimera, Allegro, Allergan, Eyepoint, Genentech, Kodiak, Novartis, Regeneron, and Santen; serving on the speakers’ bureau for Allergan, Apellis, Genentech, Mallinckrodt, Novartis, Regeneron, and Spark; and performing contracted research for Aerie, Allegro, Allergan, DRCR, Genentech, Icon, Ionis, KalVista, Kodiak, Novartis, Opthea, Optos, Regeneron, Santen, Senju, and Sydnexis. Survey participants (CRH, SDW, PYC, DJW, PEN, KJB, MSD, DSC, VRR, LMR, MS, and MAS) received an honorarium from Bausch & Lomb Americas, Inc. TB and MY are employees of Bausch + Lomb, Bridgewater, NJ.

Figures

Fig. 1
Fig. 1
Patient treatment profile. (a) New to treatment or previously received treatment. (b) Concurrent uveitis medication use
Fig. 2
Fig. 2
Reasons participants chose to use SCS-TA. aAphakia or open posterior capsule; unicameral eyes (not suitable for IVT implants); unresponsive to other treatments. FDA = US Food and Drug Administration; IVT = intravitreal; SCS-TA = acetonide suprachoroidal injection; UME = uveitic macular edema
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761–77. - PMC - PubMed
    1. Cunningham ETE, Zierhut M. Vision loss in uveitis. Ocul Immunol Inflamm. 2021;29(6):1037–9. - PubMed
    1. Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–9. - PubMed
    1. Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667–80. - PMC - PubMed
    1. Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97(5):460–72. - PubMed

Substances

LinkOut - more resources